Company Monitoring Page for Biogen

latest headlines for company on cafepharma

Big pharma holds steady on research spending
EP Vantage
Fri, 04/21/23 - 10:03 am
Tags:
R&D, AbbVie, Amgen, AstraZeneca, Bayer, Biogen, Bristol Myers Squibb, Eli Lilly, Gilead Sciences, GSK, JNJ, Merck, Merck KGaA, Moderna Therapeutics, Novartis, Novo Nordisk, Pfizer, Regeneron, Roche, Sanofi, UCB, Vertex Pharmaceuticals
Biogen buys into Denali’s amyloid beta program
Pharmaphorum
Thu, 04/13/23 - 10:05 am
Tags:
Biogen, Denali Therapeutics, Alzheimer's disease
In Another Round of Cuts, Biogen Lays Off Unspecified Number of Employees
BioSpace
Mon, 04/10/23 - 12:00 pm
Tags:
Biogen, layoffs
5 FDA decisions to watch in the second quarter
BioPharma Dive
Mon, 04/3/23 - 11:06 pm
Tags:
FDA, Sarepta Therapeutics, Duchenne Muscular Dystrophy, Biogen, tofersen, ALS, Seres Therapeutics, C. difficile, Pfizer, GSK, vaccines, RSV, Regeneron, Eylea
Go or no go? Seagen's Padcev eyes FDA approval
EP Vantage
Mon, 04/3/23 - 09:41 am
Tags:
FDA, AbbVie, Alvotech, Ascendis Pharma, Astellas, AstraZeneca, Biogen, Daiichi Sankyo, Eli Lilly, Ferring Pharmaceuticals, Hugel, Innoviva, Ionis Pharmaceuticals, Lundbeck, Merck, Novo Nordisk, Otsuka, Pfizer, Roche Seagen, Seres Therapeutics, Takeda, UCB, Vertex Pharmaceuticals
Massachusetts judge dismisses lawsuit against Biogen over failed launch of Alzheimer's drug Aduhelm
Endpoints
Thu, 03/30/23 - 11:05 pm
Tags:
Massachusetts, Biogen, Aduhelm, legal
Biogen Successfully Targets Tau in Phase Ib Alzheimer's Study
BioSpace
Thu, 03/30/23 - 11:02 pm
Tags:
Biogen, Alzheimer's disease, clinical trials
Ionis Rockets As Biogen-Partnered ALS Drug Wins Key Endorsement
Investors Business Daily
Thu, 03/23/23 - 09:58 am
Tags:
Ionis Pharmaceuticals, Biogen, ALS, FDA, tofersen
FDA advisers support conditional clearance of Biogen’s ALS drug
BioPharma Dive
Wed, 03/22/23 - 09:23 pm
Tags:
Biogen, ALS, FDA, tofersen
Neurofilament as a surrogate endpoint goes on trial in tofersen adcomm
BioSpace
Mon, 03/20/23 - 11:40 am
Tags:
ALS, Biogen, Ionis Pharmaceuticals, FDA, tofersen, clinical trials
Novartis, Biogen Scrap Gene Regulation Partnerships with Sangamo
BioSpace
Mon, 03/20/23 - 09:51 am
Tags:
Sangamo Therapeutics, Novartis, Biogen, neurology, gene regulation therapies
Alzheimer's Association campaigns for broader Leqembi coverage: report
Fierce Pharma
Fri, 03/17/23 - 11:43 am
Tags:
CMS, Eisai, Biogen, Leqembi, Alzheimer's disease
Biogen's head of neurodegeneration leaves
Fierce Biotech
Fri, 03/17/23 - 10:03 am
Tags:
Biogen, women executives, Aduhelm, Alzheimer's disease
Biogen gets EU court ruling in favor of blocking Tecfidera generic entry
Seeking Alpha
Thu, 03/16/23 - 09:44 am
Tags:
Biogen, EMA, Europe, MS, multiple sclerosis, Tecfidera, generics
VA to cover Eisai's new Alzheimer's drug after declining to cover Aduhelm
Endpoints
Mon, 03/13/23 - 04:44 pm
Tags:
VHA, Eisai, Biogen, Leqembi, Aduhelm, Alzheimer's disease
Eisai projects $7B in sales by 2030 for new Alzheimer's drug
Endpoints
Sun, 03/12/23 - 09:40 pm
Tags:
Eisai, Biogen, Alzheimer's disease, Leqembi
Biogen names Stelios Papadopoulos' successor
Fierce Biotech
Fri, 03/10/23 - 09:45 am
Tags:
Biogen, Stelios Papadopoulos, Caroline Dorsa
FDA says no adcomm planned for Biogen, Sage's depression drug
Seeking Alpha
Wed, 03/8/23 - 09:47 pm
Tags:
Biogen, SAGE Therapeutics, FDA, zuranolone, major depressive disorder, postpartum depression
FDA sets July decision date for full approval of Leqembi
BioSpace
Mon, 03/6/23 - 12:11 pm
Tags:
Eisai, Biogen, Alzheimer's disease, Leqembi, FDA, lecanemab
Despite recent approvals, significant unmet need remains in Alzheimer’s market
Clinical Trials Arena
Wed, 03/1/23 - 10:05 am
Tags:
Alzheimer's disease, Biogen, Eisai, Lundbeck, Otsuka, Avanir Pharmaceuticals, Axesome, Aduhelm, Leqembi

Pages

last 30 twitter posts

current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.